Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a report on Wednesday, February 26th.

Minerva Neurosciences Price Performance

Shares of NERV opened at $1.56 on Tuesday. The firm has a market cap of $10.91 million, a P/E ratio of -3.55 and a beta of 0.10. Minerva Neurosciences has a 1 year low of $1.42 and a 1 year high of $3.69. The company has a 50 day simple moving average of $2.00 and a two-hundred day simple moving average of $2.29.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.49. On average, sell-side analysts anticipate that Minerva Neurosciences will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Minerva Neurosciences stock. Citadel Advisors LLC raised its holdings in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,764 shares of the biopharmaceutical company’s stock after purchasing an additional 8,525 shares during the quarter. Citadel Advisors LLC owned 0.37% of Minerva Neurosciences worth $57,000 as of its most recent filing with the Securities & Exchange Commission. 34.56% of the stock is currently owned by institutional investors and hedge funds.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.